Completed PHASE1 INTERVENTIONAL 1-arm NCT05538572

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Sponsor: Prelude Therapeutics

Conditions Breast Cancer Endometrial Cancer Glioblastoma Head and Neck Squamous Cell Carcinoma Malignant Mesothelioma Non-small Cell Lung Cancers Sarcoma

Interventions PRT3645

Updated 13 times since 2022 Last updated: Jun 27, 2024 Started: Dec 27, 2022 Primary completion: Jun 26, 2024 Completion: Jun 26, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05538572, this PHASE1 trial focuses on Breast Cancer and Endometrial Cancer and remains completed. Sponsored by Prelude Therapeutics, it has been updated 13 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Aug 2024 — Sep 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE1
Feb 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1

▶ Show 8 earlier versions

Oct 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Feb 2023 — May 2023 [monthly]

Recruiting PHASE1
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Jan 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Prelude Therapeutics

Data source: Prelude Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Celebration, United States , Cleveland, United States , Fairfax, United States , Miami, United States , Nashville, United States , New Haven, United States , New York, United States , Philadelphia, United States , San Antonio, United States and 2 more locations